Clinical trial of advanced or metastatic triple-negative breast cancer with adoptive therapy of PD1-positive tumor infiltrating lymphocytes

THE TILS001 STUDY AIMS TO STUDY A NEW TYPE OF THERAPY CALLED ADOPTIVE CELL THERAPY BY INFUSION OF TUMOR INFILTRATING LYMPHOCYTES WHOSE CELLS EXPRESS A PROTEIN CALLED PD1). THE ACRONYM FOR THIS TREATMENT IS TILS PD1 WHICH STANDS FOR: TUMOR-INFILTRATING LYMPHOCYTES EXPRESSING PROGRAMMED CELL DEATH PROTEIN 1. T LYMPHOCYTES ARE PART OF THE BODY'S IMMUNE SYSTEM AND HELP FIGHT INFECTIONS AND OTHER DISEASES; INSIDE TUMORS THERE IS USUALLY A TYPE OF NATURALLY INFILTRATING T LYMPHOCYTES, HENCE THEIR NAME INFILTRATING (SO-CALLED TILS). THE AIM OF THIS STUDY IS TO EXTRACT TILS FROM THE PATIENT'S TUMOR, SELECT THOSE THAT WILL ATTACK THE TUMOR IN A MORE SPECIFIC WAY AND INCREASE THEIR NUMBER IN A LABORATORY IN ORDER TO SUBSEQUENTLY ADMINISTER THEM.